Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 126,324 shares, a drop of 38.3% from the September 30th total of 204,583 shares. Based on an average daily trading volume, of 354,271 shares, the short-interest ratio is presently 0.4 days. Currently, 15.0% of the company’s shares are sold short.
Wall Street Analyst Weigh In
MBRX has been the subject of several recent research reports. HC Wainwright decreased their price target on shares of Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research report on Friday, August 28th. Wall Street Zen upgraded shares of Moleculin Biotech from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $60.00.
View Our Latest Stock Report on MBRX
Moleculin Biotech Stock Performance
Shares of NASDAQ:MBRX traded up $0.03 during trading on Tuesday, reaching $8.35. The stock had a trading volume of 2,398 shares, compared to its average volume of 33,586. The firm’s fifty day moving average is $10.77 and its 200 day moving average is $40.34. Moleculin Biotech has a 52 week low of $3.23 and a 52 week high of $253.05. The stock has a market cap of $8.60 million, a price-to-earnings ratio of -1.17 and a beta of 2.00.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($28.00) earnings per share for the quarter, topping the consensus estimate of ($31.00) by $3.00. On average, research analysts forecast that Moleculin Biotech will post -47.40 earnings per share for the current fiscal year.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.
Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.
Further Reading
- Five stocks we like better than Moleculin Biotech
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
- MicroVision Pivots: Mapping New Ground Beyond Auto
- Are the Fears Around Alphabet’s Search Slowdown Warranted?
- Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
